Login
$HYPD
$2.43 -$0.04 (1.62%) After hours

Balance Sheets

In millions of USD, except per-share amounts
Q3 FY2026
As of Sep 30, 2026
Q2 FY2026
As of Jun 30, 2026
Q1 FY2026
As of Mar 31, 2026
Q4 FY2025
As of Dec 31, 2025
Q3 FY2025
As of Sep 30, 2025
Q2 FY2025
As of Jun 30, 2025
Q1 FY2025
As of Mar 31, 2025
Q4 FY2024
As of Dec 31, 2024
Q3 FY2024
As of Sep 30, 2024
Q2 FY2024
As of Jun 30, 2024
Q1 FY2024
As of Mar 31, 2024
Q4 FY2023
As of Dec 31, 2023
Q3 FY2023
As of Sep 30, 2023
Q2 FY2023
As of Jun 30, 2023
Q1 FY2023
As of Mar 31, 2023
Q4 FY2022
As of Dec 31, 2022
Q3 FY2022
As of Sep 30, 2022
Q2 FY2022
As of Jun 30, 2022
Q1 FY2022
As of Mar 31, 2022
Q4 FY2021
As of Dec 31, 2021
Assets
Current Assets
Cash and cash equivalents
Inventories
Deferred clinical supply costs
License fee and expense reimbursements receivable
Deposit to be refunded
Stablecoins
Prepaid expenses and other current assets
Total Current Assets
Intangible assets
Prepaid expenses, non-current
Digital assets
Property and equipment, net
Deferred offering costs
Security deposits, non-current
Digital assets receivable, net
Digital intangible assets
Digital intangible assets receivable, net
Operating lease right-of-use asset
Equipment deposits
Other assets
Total Assets
Liabilities and Stockholders' Equity
Current Liabilities:
Accounts payable
Accrued compensation
Accrued inducement grant
Accrued former licensor obligations
Accrued expenses and other current liabilities
Deferred revenue - current portion
Operating lease liabilities - current portion
Note payable - current portion, net
Convertible notes payable - net of debt discount of $0 and $263,930 as of December 31, 2025 and December 31, 2024, respectively
Total Current Liabilities
Notes payable - non-current portion, net
Accrued expenses and other non-current liabilities
Note payable - non-current portion, net
Convertible notes payable - non-current portion, net of debt discount of $0 and $398,569 as of December 31, 2024 and 2023, respectively
Operating lease liabilities, non-current portion
Total Liabilities
Stockholders' Equity
Preferred stock, $0.0001 par value, 60,000,000 shares authorized; Series A Non-Voting Convertible Preferred Stock, 5,435,898 shares designated; 5,235,897 and 5,435,897 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively with a liquidation preference of $50,766,000 as of September 30, 2026
Common stock, $0.0001 par value, 600,000,000 shares authorized; 7,162,659 and 1,506,369 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively
Common stock, $0.0001 par value, 600,000,000 shares authorized; 15,442,482 shares issued and outstanding as of September 30, 2026; 8,762,329 shares issued and 8,680,005 shares outstanding as of December 31, 2025, respectively
Additional paid-in-capital
Treasury stock, at cost, 0 and 82,324 shares as of September 30, 2026 and December 31, 2025, respectively
Accumulated deficit
Total Stockholders' Equity
Total Liabilities and Stockholders' Equity

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support